Teriparatide vs ANP (Atrial Natriuretic Peptide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Teriparatide

Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.

Full details →

ANP (Atrial Natriuretic Peptide)

ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.

Full details →

Side-by-Side Comparison

AspectTeriparatideANP (Atrial Natriuretic Peptide)
MechanismIntermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone.Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system.
Typical Dosage20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies.Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion.
AdministrationSubcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk.Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration.
Side EffectsOrthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible.Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses.
Best For

What They Have in Common

Both Teriparatide and ANP (Atrial Natriuretic Peptide) are commonly used for:

Ready to Learn More?